Kevin Kratiuk Selected Research

Treatment-Resistant Depressive Disorder

2/2024	Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.
1/2023	Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
1/2023	Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
1/2022	Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
1/2022	Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?
1/2022	Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation.
11/2021	Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence.
4/2021	Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment.
1/2021	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.
1/2021	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevin Kratiuk Research Topics

Disease

23	Treatment-Resistant Depressive Disorder 02/2024 - 02/2019
10	Bipolar Disorder (Manic Depressive Psychosis) 01/2022 - 01/2020
9	Major Depressive Disorder (Major Depressive Disorders) 10/2022 - 02/2019
7	Mood Disorders (Mood Disorder) 01/2022 - 12/2020
2	Anhedonia 01/2022 - 11/2020
1	Borderline Personality Disorder (Personality Disorders, Borderline) 01/2023
1	Neurobehavioral Manifestations 10/2022
1	Psychomotor Agitation (Akathisia) 01/2022
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022
1	Inflammation (Inflammations) 04/2021
1	Hematuria 04/2021
1	Dysuria 04/2021
1	Headache (Headaches) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Nausea 01/2021
1	COVID-19 01/2021
1	Psychotic Disorders (Schizoaffective Disorder) 08/2020
1	Mania (Manias) 08/2020

Drug/Important Bio-Agent (IBA)

24	Ketamine FDA LinkGeneric 01/2023 - 01/2020
10	Antidepressive Agents (Antidepressants)IBA 10/2022 - 02/2019
3	EsketamineIBA 04/2021 - 01/2021
1	Psilocybin (Psilocibin)IBA 02/2024
1	Immunoglobulin E (IgE)IBA 04/2021
1	Anesthetics (Anesthetic Agents)IBA 04/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	GLYX-13 peptideIBA 02/2019
1	N-Methylaspartate (NMDA)IBA 02/2019